IDEAYA Biosciences (IDYA) Projected to Post Quarterly Earnings on Tuesday

Key Points

• IDEAYA Biosciences is expected to announce its Q2 2025 earnings on August 5th, with analysts forecasting a loss of ($0.85) per share and revenue of $3.48 million.
• The company's shares opened at $25.02 on Tuesday, up 2.1%, and have a market cap of $2.19 billion.
• Recent analyst ratings for IDEAYA have been positive, with upward adjustments in price targets and a consensus rating of "Moderate Buy", alongside an average price target of $48.09.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.85) per share and revenue of $3.48 million for the quarter.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the firm posted ($0.53) earnings per share. On average, analysts expect IDEAYA Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

IDEAYA Biosciences Stock Performance

IDYA stock traded down $0.08 during trading on Friday, hitting $24.27. 860,814 shares of the company traded hands, compared to its average volume of 982,643. The firm has a market capitalization of $2.13 billion, a PE ratio of -6.76 and a beta of 0.09. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $41.08. The company has a 50-day moving average of $22.07 and a 200-day moving average of $20.35.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IDYA shares. Wells Fargo & Company started coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They set an "overweight" rating and a $44.00 target price for the company. The Goldman Sachs Group upgraded IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective for the company in a report on Thursday, July 10th. Royal Bank Of Canada upgraded IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their price objective for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. TD Cowen began coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a "buy" rating for the company. Finally, JPMorgan Chase & Co. increased their price objective on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a report on Monday, July 28th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $48.09.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC increased its position in IDEAYA Biosciences by 345.2% during the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company's stock valued at $8,970,000 after buying an additional 424,625 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of IDEAYA Biosciences by 30.1% in the 1st quarter. Royal Bank of Canada now owns 122,460 shares of the company's stock worth $2,006,000 after purchasing an additional 28,322 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of IDEAYA Biosciences by 8.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company's stock worth $938,000 after purchasing an additional 4,308 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company's stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.